(Incorporated in Delaware) Our company is focused on the development and commercialization of a new class of immunotherapeutics for the treatment of solid tumors. This new class of drugs, sometimes referred to as “live biopharmaceuticals” are genetically modified biological agents which have the capability of expressing select anti-tumoral agents within the tumor’s microenvironment. Our lead program, […]

(Incorporated in Delaware) We are a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. Our vision is to program biology to generate optimal therapeutics for the greatest impact on human health. Central to our vision is the Generate Platform, designed to be a therapeutic area and protein modality […]

(Incorporated in the Cayman Islands) We are a newly organized blank check company. We are part of the Spring Valley family of investment vehicles focused on the power infrastructure and decarbonization sectors, which together have raised approximately $690 million across three IPOs. Our purpose is to partner with an innovative, high – growth business using proprietary […]

(Incorporated in the Cayman Islands) We are a newly organized blank check company. We have not selected a specific sector or industry as a focus in our search for acquisition targets. Through our management team, we expect to have differentiated access to deal flow extending beyond the U.S., with a particular focus on Europe. Lorin […]

Note: This is NOT an IPO. This is a Direct Listing by Polaryx Therapeutics (PLYX Proposed) on the NASDAQ. Maxim Group is the financial advisor for this Direct Listing. (Incorporated in Nevada) We are a clinical-stage biotechnology company developing novel therapies for rare pediatric lysosomal storage disorders (LSDs). In the first half of 2026, we […]

Note: This is NOT an IPO. This is a NASDAQ Direct Listing. No new stock is being offered. Existing shareholders are selling stock. No underwriters are involved in a direct listing. Maxim Group is the financial advisor. We develop treadmills for Virtual Reality (VR) and Augmented Reality (AR) gaming as well as for fitness. Note: […]

(Incorporated in Delaware) Note: MiniMed is going public in a spin-off from its parent, Medtronic. Among leading diabetes device manufacturers as identified by Seagrove Partners, we have the largest global footprint in our industry, operating in approximately 80 countries, and with more than 640,000 insulin pump users as of October 2025. According to Seagrove Partners’ […]

(Incorporated in the Cayman Islands) We are a newly established blank check company, managed by the top executives of Terrapin Partners. We intend to target companies with an enterprise value between $500 million and $2 billion that benefit from new technology or that provide tech products and services. The senior members of our management team […]

(Incorporated in the Cayman Islands) We are a holding company incorporated in the Cayman Islands. All substantive business operations are conducted by our Hong Kong subsidiary, Cloud Data HK, which is an integrated internet infrastructure service provider. As companies move ahead with digital transformation strategies, adopt cloud-based architectures, or expand reach across multiple regions around the […]

(Incorporated in the Cayman Islands)  We are a clinical biopharmaceutical company in Malaysia with a focus on the development of pharmaceutical-grade botanical therapeutic treatments for obesity and metabolic syndrome. Our lead product candidate, SKF7® , is a patented standardized extract of Labisia pumila, a medicinal plant indigenous to Malaysia, that is being developed to treat abdominal […]